Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

SpringWorks Therapeutics Inc

Healthcare US SWTX

NoneUSD
-(-%)

Last update at 2025-07-30T13:05:02.506751Z

Day Range

--
LowHigh

52 Week Range

18.0053.92
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap3134.60M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-357.10202M
  • Revenue TTM26.45M
  • Revenue Per Share TTM0.40
  • Gross Profit TTM 35.00M
  • Diluted EPS TTM-5.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -277.41700M -173.91000M -45.57400M -58.30600M -17.81300M
Minority interest - - - - -
Net income -274.16000M -173.21200M -44.24400M -54.75900M -17.81300M
Selling general administrative 134.55M 71.79M 29.46M 16.69M 8.59M
Selling and marketing expenses - - - - -
Gross profit 6.15M - 35.00M - -
Reconciled depreciation 0.77M 0.49M 0.35M 0.19M 0.02M
Ebit -281.43900M -173.46800M -46.32400M -59.23900M -18.49100M
Ebitda -280.67400M -172.97800M -45.97500M -59.04700M -18.47400M
Depreciation and amortization 0.77M 0.49M 0.35M 0.19M 0.02M
Non operating income net other - - - - -
Operating income -280.67400M -173.46800M -46.32400M -59.23900M -18.49100M
Other operating expenses 280.67M 173.47M 81.32M 59.24M 18.49M
Interest expense -0.76500M 0.44M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 6.29M 0.70M 1.33M 3.55M 0.68M
Net interest income 6.29M 0.70M 1.33M 3.55M 0.68M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.25700M -0.69800M -1.33000M -3.54700M 0.68M
Total revenue 6.15M 0.00000M 35.00M 0.00000M 0.00000M
Total operating expenses 280.67M 173.47M 81.32M 59.24M 18.49M
Cost of revenue - - - - -
Total other income expense net 3.26M -0.44200M 0.75M 0.93M 0.68M
Discontinued operations - - - - -
Net income from continuing ops -277.41700M -173.91000M -45.57400M -58.30600M -17.81300M
Net income applicable to common shares -277.41700M -173.91000M -45.57400M -50.57700M -17.81300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 725.79M 630.24M 452.49M 576.19M 334.83M
Intangible assets 11.20M - - - -
Earning assets - - - - -
Other current assets 12.68M 7.55M 9.41M 4.91M 3.71M
Total liab 99.57M 72.05M 30.10M 19.13M 12.76M
Total stockholder equity 626.22M -569.93000M 422.40M 557.06M 322.07M
Deferred long term liab - - - - 0.70M
Other current liab 65.57M 39.24M 25.38M 14.88M 9.32M
Common stock 0.00700M 0.00600M 0.00500M 0.00500M 0.00400M
Capital stock 0.00700M 0.00600M 0.00500M 0.00500M 0.00400M
Retained earnings -895.03400M -569.93000M -292.51300M -118.60300M -73.02900M
Other liab - 16.23M - 0.16M 0.79M
Good will - - - - -
Other assets - 3.23M 3.27M 2.57M 1.70M
Cash 176.05M 67.49M 103.96M 147.09M 327.65M
Cash and equivalents - - - - -
Total current liabilities 78.17M 51.05M 29.97M 17.61M 11.97M
Current deferred revenue 4.14M 3.31M - - -
Net debt -168.99600M -62.23900M -102.67000M -144.35500M -327.65200M
Short term debt 1.06M 0.48M 1.16M 1.38M -
Short long term debt - - - - -
Short long term debt total 7.06M 5.25M 1.29M 2.73M -
Other stockholder equity 1520.06M 0.76M 715.22M 675.62M 395.10M
Property plant equipment - 18.27M 4.20M 3.02M 0.80M
Total current assets 500.91M 599.76M 382.91M 513.40M 331.36M
Long term investments 185.34M 8.99M 62.11M 57.21M 0.98M
Net tangible assets - 558.19M 422.40M 557.06M 322.07M
Short term investments 303.15M 524.72M 269.54M 361.39M -
Net receivables 5.93M - - - -
Long term debt - - - - -
Inventory 3.10M - - - -
Accounts payable 7.40M 8.01M 3.43M 1.35M 2.65M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.19M -0.76700M -0.31200M 0.04M -334.83100M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00500M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.25M 3.23M 3.27M 2.57M 1.70M
Deferred long term asset charges - - - - -
Non current assets total 224.88M 30.48M 69.58M 62.79M 3.47M
Capital lease obligations 7.06M 5.25M 1.29M 2.73M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -215.59700M 85.61M -418.83200M -4.26000M -0.29300M
Change to liabilities 23.71M 2.07M -1.30400M 1.88M 0.49M
Total cashflows from investing activities -215.59700M 83.59M -418.83200M -4.26000M -0.29300M
Net borrowings - - - - -
Total cash from financing activities 340.70M 1.16M 270.49M 333.71M 50.38M
Change to operating activities 14.39M 3.04M 2.65M 3.07M 2.07M
Net income -277.41700M -173.91000M -45.57400M -58.30600M -17.81300M
Change in cash -36.45800M -43.12800M -180.53800M 282.00M 35.38M
Begin period cash flow 104.53M 147.65M 328.19M 46.19M 10.27M
End period cash flow 68.07M 104.53M 147.65M 328.19M 45.65M
Total cash from operating activities -161.56300M -127.87700M -32.19100M -47.44400M -14.70600M
Issuance of capital stock 340.07M 0.00000M 269.59M 333.69M 50.38M
Depreciation 0.77M 0.49M 0.35M 0.19M 0.02M
Other cashflows from investing activities - - - -3.59000M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -1.34100M - - 333.71M 50.38M
Other cashflows from financing activities 1.98M 1.16M 0.89M 163.98M 50.38M
Change to netincome 76.99M 40.42M 11.69M 5.72M 1.07M
Capital expenditures 10.20M 2.02M 0.64M 0.67M 0.29M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 38.10M 5.12M 1.35M 4.95M 2.02M
Stock based compensation 72.97M 38.44M 10.03M 3.11M 1.07M
Other non cash items 4.02M 0.99M 1.05M 2.61M -
Free cash flow -171.75900M -129.89300M -32.83300M -48.11400M -14.99900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SWTX
SpringWorks Therapeutics Inc		 - -% - - - 581.25 5.06 494.84 -7.8964
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics Inc

100 Washington Boulevard, Stamford, CT, United States, 06902

Key Executives

Name Title Year Born
Mr. Saqib Islam J.D. CEO & Director 1970
Mr. Francis I. Perier Jr., M.B.A. Chief Financial Officer 1960
Dr. Badreddin Edris Ph.D. Chief Operating Officer 1987
Mr. Bhavesh Ashar Chief Commercial Officer 1966
Mr. Michael P. Nofi Chief Accounting Officer 1971
Ms. Kim Diamond VP of Communications & Investor Relations NA
Mr. Herschel S. Weinstein J.D. Gen. Counsel & Sec. 1956
Mr. Daniel J. Pichl Chief People Officer 1983
Dr. L. Mary Smith PH.D. Chief Devel. Officer 1967
Dr. James Cassidy M.D., Ph.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.